A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

Neurology

Volumn 77, Issue 16, 2011, Pages 1551-1560

  Freedman, M S ^a   Bar Or, A ^b   Oger, J ^c   Traboulsee, A ^c   Patry, D ^d   Young, C ^e   Olsson, T ^f   Li, D ^c   Hartung, H P ^g   Krantz, M ^h   Ferenczi, L ^h   Verco, T ^h  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h BioMS Medical Corp   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIRUCOTIDE; HLA DR2 ANTIGEN; HLA DR4 ANTIGEN; PLACEBO;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BACKACHE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE EXPRESSION; HAPLOTYPE; HOT FLUSH; HUMAN; INJECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; MUSCULOSKELETAL CHEST PAIN; MYELODYSPLASTIC SYNDROME; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERIPHERAL COLDNESS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RELAPSE; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 82955198543     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318233b240     Document Type: Article

References (29)

1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452. (Pubitemid 14237132)
2. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
3. Kappos L, Polman C, Pozilli C, et al. Final analysis of the European multicenter trial on IFB beta-1b in secondary progressive MS. Neurology 2001;57:1969-1975. (Pubitemid 33126860)
4. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001;56:1496-1504.
5. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-687.
6. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795.
7. Kappos L, Weinshenker B, Pozzilli C, et al. for the European (EU-SPMS) and North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committees and Independent Advisory Boards. Interferon beta-1b in secondary progressive MS; a combined analysis of the two trials. Neurology 2004;63: 1779-1787. (Pubitemid 39532369)
8. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomized, double blind, placebo controlled phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706-710. (Pubitemid 38526680)
9. Wolinsky JS, Narayana PA, O'Connor P, et al, and the PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial Ann Neurol 2007;61:14-24. (Pubitemid 46214240)
10. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
11. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010;133:1900-1913.
12. Frischer JM, Bramow S, Dal-Bianco A, et al. the relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175-1189.
13. Holmoy T. Immunopathogenesis of multiple sclerosis: concepts and controversies. Acta Neurol Scand Suppl 2007;187:39-45. (Pubitemid 46535913)
14. Kasper LH, Shoemaker J. The healthy immune system vs the MS immune system. Neurology 2010;74:S2-S8.
15. Warren KG, Catz I, Steinman L. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features. Proc Natl Acad Sci USA 1995;92:11061-11065.
16. Sakai K, Zamvil SS, Mitchell DJ, et al. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol 1988;19:21-32.
17. Wucherpfennig KW, Catz I, Hausmann S, et al. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T-cell clones from multiple sclerosis patients: identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 1997; 100:1114-1122. (Pubitemid 27386295)
18. Warren KG, Catz I. Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis. Ann Neurol 1986;20:20-25. (Pubitemid 16063231)
19. Warren KG, Catz I. Administration of myelin basic protein synthetic peptides to multiple sclerosis patients. J Neurol Sci 1995;133:85-94.
20. Warren KG, Catz I. The effect of intrathecal MBP synthetic peptides containing epitope P85VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis. J Neurol Sci 1997;148:67-78. (Pubitemid 27149526)
21. Warren KG, Catz I, Wucherpfennig KW. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85VVHFFKNIV96 in chronic progressive multiple sclerosis. J Neurol Sci 1997; 152:31-38. (Pubitemid 27469708)
22. Warren KG, Catz I. Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP85VVHFFKNIVTP96RT in multiple sclerosis patients. Mult Scler 2000;6:300-311.
23. Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006;13:887-895. (Pubitemid 44124687)
24. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882. (Pubitemid 29219261)
25. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I: conceptual framework and item selection. Med Care 1992;30:473-483.
26. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187-206.
27. Lipkovich I, Dmitrienko A, Su E, Denne J, Enas G. Identification of promising subgroups in the retrospective analysis of clinical trials. Available at: http://bass.georgiasouthern.edu/PDFs/BASS%202008%20Ilya%20Lipkovich.pdf. Accessed January 5, 2011.
28. Selmaj K, Verco T, Ossana M, et al. A double-blind, placebo-controlled multicenter study to evaluate dirucotide in relapsing-remitting multiple sclerosis. Poster presentation, ECTRIMS, Dusseldorf, Germany, September 9-12, 2009, poster number P778.
29. Hommes OR, Sorensen PS, Fazekas F, et al, for the European Study on Immunoglobulin in Multiple Sclerosis. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomized placebo-controlled trial. Lancet 2004;364:1149-1156. (Pubitemid 39296602)